Alex Lugovoy - Adial Pharmaceuticals Chief Officer
| ADIL Stock | USD 1.31 0.14 9.66% |
Insider
Alex Lugovoy is Chief Officer of Adial Pharmaceuticals
| Address | 1180 Seminole Trail, Charlottesville, VA, United States, 22901 |
| Phone | 434 422 9800 |
| Web | https://www.adialpharma.com |
Adial Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.8224) % which means that it has lost $0.8224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9027) %, meaning that it created substantial loss on money invested by shareholders. Adial Pharmaceuticals' management efficiency ratios could be used to measure how well Adial Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -1.72. The value of Return On Capital Employed is expected to slide to -1.77. At this time, Adial Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 1.6 M this year, although the value of Net Tangible Assets will most likely fall to about 2.7 M.Similar Executives
| Found 6 records | INSIDER Age | ||
| Edward DVM | SAB Biotherapeutics | N/A | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Eddie Sullivan | SAB Biotherapeutics | 57 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Jeffrey PharmD | Nutriband | 54 | |
| Gerald Goodman | Nutriband | 76 | |
Management Performance
| Return On Equity | -1.9 | ||||
| Return On Asset | -0.82 |
Adial Pharmaceuticals Leadership Team
Elected by the shareholders, the Adial Pharmaceuticals' board of directors comprises two types of representatives: Adial Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adial. The board's role is to monitor Adial Pharmaceuticals' management team and ensure that shareholders' interests are well served. Adial Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adial Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tony Goodman, COO Director | ||
| Alex Lugovoy, Chief Officer | ||
| Catherine Fratila, Controller | ||
| MBA MBA, Treasurer CFO | ||
| Lawrence CPA, Controller | ||
| John JD, General Counsel | ||
| Cary MBA, President CEO | ||
| DSc FRCPsych, Founder Officer | ||
| Mark Peikin, Chief Officer | ||
| Jack Reich, Head Regulatory |
Adial Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adial Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.9 | ||||
| Return On Asset | -0.82 | ||||
| Current Valuation | 3.01 M | ||||
| Shares Outstanding | 4.23 M | ||||
| Shares Owned By Insiders | 4.03 % | ||||
| Shares Owned By Institutions | 7.75 % | ||||
| Number Of Shares Shorted | 132.32 K | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 2.31 X | ||||
| EBITDA | (6.89 M) |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Adial Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Adial Stock
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.98) | Return On Assets (0.82) | Return On Equity (1.90) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.